"Cetuximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.
Descriptor ID |
D000068818
|
MeSH Number(s) |
D12.776.124.486.485.114.224.060.750 D12.776.124.790.651.114.224.060.750 D12.776.377.715.548.114.224.200.750
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cetuximab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Cetuximab [D12.776.124.486.485.114.224.060.750]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Cetuximab [D12.776.124.790.651.114.224.060.750]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Cetuximab [D12.776.377.715.548.114.224.200.750]
Below are MeSH descriptors whose meaning is more specific than "Cetuximab".
This graph shows the total number of publications written about "Cetuximab" by people in this website by year, and whether "Cetuximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2004 | 0 | 2 | 2 |
2005 | 0 | 1 | 1 |
2006 | 0 | 4 | 4 |
2007 | 0 | 4 | 4 |
2008 | 0 | 5 | 5 |
2009 | 0 | 4 | 4 |
2010 | 0 | 5 | 5 |
2011 | 0 | 3 | 3 |
2012 | 0 | 4 | 4 |
2013 | 0 | 1 | 1 |
2014 | 0 | 8 | 8 |
2015 | 0 | 2 | 2 |
2016 | 2 | 1 | 3 |
2017 | 1 | 4 | 5 |
2018 | 4 | 3 | 7 |
2019 | 1 | 4 | 5 |
2020 | 4 | 2 | 6 |
2021 | 1 | 3 | 4 |
2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cetuximab" by people in Profiles.
-
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2022 12; 135:106219.
-
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. Am J Clin Oncol. 2022 08 01; 45(8):366-372.
-
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447.
-
Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis. Head Neck. 2022 07; 44(7):1528-1544.
-
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887.
-
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289.
-
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 06; 22(6):883-892.
-
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. J Natl Cancer Inst. 2021 02 01; 113(2):171-181.
-
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):733-741.
-
Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. Br J Cancer. 2021 01; 124(1):176-182.